Our Pipeline

Our lead vaccine candidate answers a huge and urgent unmet medical need

Our Lead Candidate,CMV is a disease with life-threatening implications, particularly for babies and children. There is currently a lack of effective treatment or prevention for CMV.

We chose this candidate for four reasons:

There is a huge and urgent unmet medical need for an effective vaccine.
It is commercially appealing given the size of the target population and pricing potential.
The immunology is well understood, allowing us to demonstrate proof of concept with a very high degree of confidence.
Progress to develop a vaccine for this disease has in the past lacked the technology that we have at our disposal and want to showcase.

(CMV) Cytomegalovirus

Our CMV vaccine candidate targets a key unmet need worldwide. CMV is the most common virus that most people have never heard of, even though it has now been identified as a high priority for vaccines development by key authorities such as the FDA and Institute of Medicine.

In the developed world, CMV infects 50-80% of adults before they reach their fortieth birthday and around 30% of children under five years old. It is even more widespread in developing countries. Infection is typically asymptomatic and not harmful to healthy individuals. However, the virus can cause serious complications in groups with weak immune systems such as elderly people, transplant recipients and infants infected in utero. In these patients, infection can cause severe and life-threatening complications including birth defects and organ failure.

Congenital CMV occurs when CMV is transferred from a pregnant woman to her fetus in utero and has a very high disease burden. In many parts of the world it is second only to cerebral palsy as a cause of serious infant malformation. In the United States 5,000 infants each year develop permanent conditions including deafness, blindness and neurologic disorders from CMV. Overall, it affects more live births in the US than Fetal Alcohol Syndrome or Down’s and is estimated to generate over $2 billion in healthcare costs annually.

 

                                          (EBV) Epstein-Barr Virus

 

Epstein-Barr Virus (EBV) is the primary agent of infectious mοոοոսϲlеοѕiѕ (IM) and is associated with the development of B cell lymphomas, T cell lymphomas, Hodgkin lymphoma, nasopharyngeal ϲаrсiոοma, and gastric carcinomas. Several studies have also now shown that EBV infection is more prevalent in patients with multiple sclerosis (MS), and that EBV may be a cofactor (32-fold higher risk) in the development of MS.  Therapeutic antivirals have shown no clinical benefit, making a preventative vaccine approach highly needed.

The target product would be a prophylactic vaccine for use in the pediatric and adult populations to prevent EBV infection.

It is estimated that the CMV vaccine market could exceed $1.0 -1.5 billion of sales annually.

The market opportunity for a vaccine against IM has been estimated at $1.0-1.5 billion, while the opportunity for a vaccine for MS is estimated as high as $10 billion.

Scroll to Top